Evaluation of Three Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and RSV/276 in RSV Seronegative Children
Open Access
- 3 October 2026
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Abstract
Background: A respiratory syncytial virus (RSV) vaccine, eliciting active immunity could significantly impact child health. This study evaluated 3 intranasal live-attenuated candidate RSV vaccines, RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and RSV/276 to placebo. Methods: Healthy, RSV-seronegative children aged 6–24 monthswere randomized to receive 1 of 3 candidate vaccines or placebo. Participants were monitored for vaccine reactogenicity and RSV serum antibodies. Results: Between years 2019 and 2023, 67 participants were randomized, 20 each to RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and placebo and 7 to RSV/276. The RSV/276 arm closed early due to an excess of mild cough in another study. The proportion (95% CI) of children experiencing at least 1 solicited adverse event during the 28 days after inoculation was 55% (32%, 77%) in RSV/ΔNS2/Δ1313/I1314L, 40% (19%, 64%) in RSV/6120/ΔNS2/1030s, 71% (29%, 96%) in RSV/276, and 55% (32%, 77%) in placebo. Events were mostly Grade 1 and often associated with other viruses. The proportion of children with ≥4-fold increase in serum RSV-neutralizing antibody titer in each vaccine arm (>70%) was significantly greater than the placebo arm (15%). Conclusions: RSV/ΔNS2/Δ1313/I1314L and RSV/6120/ΔNS2/1030s had excellent safety and immunogenicity;assessment of RSV/276 was limited by the small sample size. RSV/ΔNS2/Δ1313/I1314L and RSV/6120/ΔNS2/1030s were deemed suitable for further evaluation. Clinical Trials Registration: NCT03916185.Keywords
Funding Information
- International Maternal Pediatric Adolescent AIDS Clinical Trials Network
- National Institute of Allergy and Infectious Diseases
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Mental Health
- National Institutes of Health (UM1AI068632)
- National Institutes of Health (UM1AI068616)
- National Institutes of Health (UM1AI106716)
- National Institutes of Health (AI000326-43)
- National Institute of Child Health and Human Development (HHSN275201800001I)
- Norges Idrettshøgskole
- National Institute of Allergy and Infectious Diseases (HHSN272200900010C)
- National Institute of Allergy and Infectious Diseases (75N93019D00031)
- Sanofi Australia
- National Center for Advancing Translational Sciences (TR004399)
- U.S. Department of Health and Human Services
This publication has 26 references indexed in Scilit:
- Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational studyThe Lancet Infectious Diseases, 2025
- Full 2023–24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL studyThe Lancet Infectious Diseases, 2024
- The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global accessThe Lancet Infectious Diseases, 2024
- Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscapeThe Lancet Infectious Diseases, 2022
- Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysisThe Lancet, 2022
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term InfantsNew England Journal of Medicine, 2022
- Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control studyThe Lancet, 2019
- Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling studyThe Lancet, 2017
- Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virusScientific Reports, 2016
- The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccinesVaccine, 2007